The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.
About the PMCPA
The Prescription Medicines Code of Practice Authority was established by the Association of the British Pharmaceutical Industry to operate the ABPI Code of Practice for the Pharmaceutical Industry independently of the ABPI.
Anyone with any concerns about the activities of a pharmaceutical company is welcome to contact the PMCPA at email@example.com
The PMCPA is a division of the ABPI, which is a company limited by guarantee registered in England and Wales no 09826787, registered office 7th Floor Southside, 106 Victoria Street, London SW1E 6QT 0207 747 8880.
The ABPI Code of Practice for the Pharmaceutical Industry covers: